Altimmune reports Phase 2b IMPACT 48-week pemvidutide data in MASH showing higher composite response rates vs placebo

Altimmune announced Phase 2b IMPACT 48-week pemvidutide data in MASH, showing significantly higher composite response rates for liver inflammation, fibrosis improvement and disease remission versus placebo, supporting Phase 3 development.

Detected & updated continuously · Source: Nebula